Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

NCT03756883 PHASE3 COMPLETED Results posted

A randomized, multiple-dose, blinded, placebo-controlled, parallel-group, multiple-center bioequivalence study with pharmacodynamic endpoints

Details

Lead sponsor	Actavis Inc.
Phase	PHASE3
Status	COMPLETED
Enrolment	999
Start date	Mon Dec 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Nov 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Asthma

Interventions

• Fluticasone Propionate and Salmeterol Inhalation Powder
• Fluticasone Propionate and Salmeterol Inhalation Powder
• Placebo Inhalation Powder

Countries

United States